AZD5363

Catalog No.S8019

AZD5363 Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. AZD5363 purchased from Selleck.

    Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. AZD5363 purchased from Selleck.

  • LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. AZD5363 purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO0NlAxKG6P NVnodotkPiCm M2Hwd4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= MlHSNlY{PTF|MkO=
ZR75 M2P3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XH[VExOCCwTR?= NFjBZXo3KGR? NInZNnlqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= M2jlNFI3OzVzM{Kz
T74D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;J[lExOCCwTR?= NIDwNXA3KGR? NH7LWoFqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= NF7ocWszPjN3MUOyNy=>
1%MCF7 M4fOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2xSnRLPDByIH7N MkfYOkBl M4HubYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= M4fyUVI3OzVzM{Kz
MCF7 LTED NWjVb4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJTVIxOCCwTR?= M1yy[VYh\A>? M4L1Rolv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NUjObnh3OjZ|NUGzNlM>
ZR75 LTED NXu4XGpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFNVAxKG6P NYDObHNoPiCm M{HsOIlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NHnYXIszPjN3MUOyNy=>
T74D LTED M2ftS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nRdlExOCCwTR?= M13TUFYh\A>? NUCyd|NVcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M{H6RlI3OzVzM{Kz
TamR NFnr[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy0NFAhdk1? M3zFeVYh\A>? M17BR4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= M4nHW|I3OzVzM{Kz
HCC1954 NFHBe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILtR5oxNTFwM{Wg{txO MV21JIQ> NUnDSZFz\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= M2KwXlI3ODl3NEe1
BT474c NXfVb5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFroUo0xNTFwM{Wg{txO NITTTFI2KGR? NIXmNW5mdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl|MR?= MXyyOlA6PTR5NR?=
KPL4 NUXVZZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy4SmFOOC1zLkO1JO69VQ>? MYC1JIQ> MXjlcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>? NV3NeohMOjZyOUW0O|U>
SKBR3 NH34XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq3b28xNTFwM{Wg{txO M2X5[VUh\A>? M{HCe4VvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz NIixbXozPjB7NUS3OS=>
MR49C NEHIeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMVUh|ryP MXW0PEBp MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Ml;ZNlUyPTFyMUK=
MR49F MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTXNE02KM7:TR?= Mn\COFghcA>? NGPNcoxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3vkTFI2OTVzMEGy
NCI-H522 NHnEWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzpXYc2UUN3ME2xNU4{KCkEsUKuO{kh|ryP MlzTNlQ6PTd4OEK=
PC-9 M3;lbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7OUIhKSzVyPUmuN{ApyrFzLkKpJO69VQ>? M3TpZ|I1QTV5Nkiy
NCI-H522 MY\GeY5kfGmxbjDBd5NigQ>? NGnNZZQyNzVxMUCg{txO MmPoOE8zPCCq NVL6NYhlcW6lcnXhd4V{KEGNVDDwbI9{eGixconsZZRqd25? MkHuNlQ6PTd4OEK=
PC-9 MmPRSpVv[3Srb36gRZN{[Xl? NUDCRm5NOS93L{GwJO69VQ>? NWrFT5k3PC9{NDDo M37rfIlv[3KnYYPld{BCU1RicHjvd5Bpd3K7bHH0bY9v Mnv5NlQ6PTd4OEK=
HGC27 M13uZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHGWFR[UUN3ME2wMlQ1PSEQvF2= NWK5bXpkOjRyOEizPFI>
IM95m MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHabpNKSzVyPUCuOVEh|ryP NGLsfXIzPDB6OEO4Ni=>
AGS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7hNphKSzVyPUCuOVUzKM7:TR?= NF;WO48zPDB6OEO4Ni=>
NCI-N87 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r3NmlEPTB;MT6wN|ch|ryP MUCyOFA5QDN6Mh?=
23132/87 NYHo[ZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnO3TWM2OD1zLk[3NUDPxE1? NHrKVXAzPDB6OEO4Ni=>
MKN1 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPCWHVKSzVyPUKuOFIyKM7:TR?= MmTqNlQxQDh|OEK=
SNU-620 NHPCeYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjOOoNMUUN3ME2zMlM5PCEQvF2= MYmyOFA5QDN6Mh?=
SNU-638 NGjMbItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\GTY5mUUN3ME20MlUzOyEQvF2= NID1S4IzPDB6OEO4Ni=>
SNU-1 M{i2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmezTWM2OD13LkK1PEDPxE1? M2j3S|I1ODh6M{iy
SNU-601 MlvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTwbZVKSzVyPUWuPVM5KM7:TR?= M1L5RlI1ODh6M{iy
SNU-668 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrRTWM2OD14LkCwN{DPxE1? NEjCOnUzPDB6OEO4Ni=>
HS746T MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnEV5pKSzVyPU[uNFg1KM7:TR?= MmK5NlQxQDh|OEK=
KATO III NHvyUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOxboNKSzVyPUeuNlY4KM7:TR?= M2PKblI1ODh6M{iy
SNU-484 NU\QRZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrnTWM2OD15LkO5NkDPxE1? NUfh[pdIOjRyOEizPFI>
SNU-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTFzLkC5O{DPxE1? MVqyOFA5QDN6Mh?=
OCUM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHkTWM2OD1zND61NVUh|ryP M2TafVI1ODh6M{iy
NUGC-3 NG[1RZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3mTWM2OD1{MT64O|Mh|ryP NYrrTGd2OjRyOEizPFI>
AZ521 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjs[YRKSzVyPUK1MlQ1QCEQvF2= MXWyOFA5QDN6Mh?=
SNU-216 NHjYRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLCTWM2OD1|MDFOwG0> NF;DV|MzPDB6OEO4Ni=>
NUGC-4 M3fLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[xSWlEPTB;M{Cg{txO MoTINlQxQDh|OEK=
SNU-5 M3exZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HobGlEPTB;M{Cg{txO M3q3T|I1ODh6M{iy
GTL-16 NWi0eoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kbIJKSzVyPUOwJO69VQ>? MXWyOFA5QDN6Mh?=
MKN74 NVrhdYE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnrNJY3UUN3ME2zNEDPxE1? MYWyOFA5QDN6Mh?=
PAMC82 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXqTWM2OD1|MDFOwG0> MUeyOFA5QDN6Mh?=
LNCaP MUDGeY5kfGmxbjDBd5NigQ>? NGDzN3Q2KM7:TR?= Ml3QNE0zPCCq M3j4b4lv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MlnXNlM6PjZ4MkG=
C4-2  NYTkToYyTnWwY4Tpc44hSXO|YYm= NHXFUYQ2KM7:TR?= M3PwNFAuOjRiaB?= NE\pRXZqdmS3Y3XzJGFMXFN2N{OgZY5lKEGNVGSzNFgheGixc4Doc5J6dGG2aX;uJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy NXTpUotUOjN7Nk[2NlE>
LNCaP MnvxSpVv[3Srb36gRZN{[Xl? NFrxU|Q2KM7:TR?= MnzLNE0zPCCq MVrpcohq[mm2czDwbI9{eGixconsZZRqd25ib3[geIhmKGSrc4ThcEBCU1RvcHH0bJdigSCkaX;tZZJs\XK|IHnuZ4x2\GmwZzDQVmFUPDBuIHXJSlRGNCB2RT3CVFEtKG2WT2KsJIFv\CCSN{CgV|Yhc2mwYYPlJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NF:xUmkzOzl4Nk[yNS=>
C4-2  NGOzR2pHfW6ldHnvckBCe3OjeR?= MX[1JO69VQ>? NXi3c29TOC1{NDDo M4LiZolvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MlX2NlM6PjZ4MkG=
LNCaP NUfUPFVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHSfnoyNTFyMECwJI5O MYWwMVMh\A>? M1jaOIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M{S5OlI{QTZ4NkKx
C4-2  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nGdlEuOTByMECgcm0> MUiwMVMh\A>? Mlj4bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MlG0NlM6PjZ4MkG=
LNCaP MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPn[G8yODBvNUCwNEBvVQ>? M{nWbFczKGh? NF\ndG5qdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJINmdGy|IIXu[IVz\2:rbnegZ4VtdCCmZXH0bC=> M{WzXVI{QTZ4NkKx
C4-2  M1nGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITpcVEyODBvNUCwNEBvVQ>? MoK1O|IhcA>? NYC3UllRcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> M2n5OVI{QTZ4NkKx
PC-3 M1nOVmZ2dmO2aX;uJGF{e2G7 MnHINE42NzFxMUCg{txO NWK4fFFvPDhiaB?= Mljh[I94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJIRwf26|dILlZY0heGG2aIfhfUBxem:2ZXnud{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIjyclQzOzJ3OEe0NC=>
DU145  M2\Cb2Z2dmO2aX;uJGF{e2G7 M1\HNVAvPS9zL{GwJO69VQ>? NX3yUI1MPDhiaB?= NE[2Z4tld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVTkOmFNOjN{NUi3OFA>
LNCaP NH30TG1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{TENVAuOTByMDDuUS=> NYC3RWtmOC12IHS= NXfud2g1emWmdXPl[EBNVkOjUDDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?= NXXDOII2OjN{NUi3OFA>
PC-3  MX7GeY5kfGmxbjDBd5NigQ>? MWSxNEDPxE1? NVLXTo9WOTJiaB?= NFjx[ZdqdmS3Y3XzJIF2fG:yaHHnfS=> MXmyN|I2QDd2MB?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02576444 Recruiting Cancer Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|Yale University November 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT02664935 Recruiting Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centre Network March 2015 Phase 2
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 2015 Phase 2
NCT02525068 Recruiting Adenocarcinoma of the Prostate Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust December 2014 Phase 2
NCT02208375 Recruiting Breast Cancer|Malignant Female Reproductive System Neoplasm M.D. Anderson Cancer Center|AstraZeneca|National Cancer Institute (NCI) November 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy AZD5363 | AZD5363 supplier | purchase AZD5363 | AZD5363 cost | AZD5363 manufacturer | order AZD5363 | AZD5363 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID